Open an account

Serina Therapeutics

SER · NYSE American

$1.66+$0.01 (+0.61%)TodayMarket closed ·
Prev close $1.65

SER analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $9.69 (+483.7% upside)

Low
$8.08
Now
$1.66
High
$11.55

Upgrades and downgrades

The latest rating actions, newest first

SER analyst upgrades, downgrades and rating actions
FirmDateActionRating
BTIGSep 10, 2026MaintainsBuy
BTIGJul 1, 2026InitiatesBuy

The case for and against

Updated Oct 17, 2026

Bull case

Serina Therapeutics is attractive because its POZ platform targets a large unmet need: converting short-acting, peak-heavy drugs into smoother zero-order release therapies that can improve efficacy and tolerability, a feature already shown for a test compound and now being tested in SER-252. Its lead asset in advanced Parkinson’s disease is supported by a 505(b)(2) pathway secured in August 2025, which reduces regulatory burden by leveraging established apomorphine safety data, while the addressable U.S. targeted PD market was about $1.8B in 2023 and growing. With first PD patient data expected around the end of 2026, continued readouts over the next 18 months or so, and a cited 50% probability of success, the stock benefits from a de-risked clinical catalyst and meaningful partnering potential.

Bear case

Serina Therapeutics is a clinical-stage biotechnology company with no approved products, limited operating history, and significant operating losses since inception, so its valuation depends heavily on a narrow pipeline rather than recurring commercial revenue from its grant-revenue segment. The bearish case centers on execution and financing risk, including the need for substantial additional capital, prior FDA hold uncertainty, and a competitive Parkinson’s disease market where standard therapies and newer products may be hard to displace. Near-term downside is amplified by binary clinical risk around the upcoming P1b readout for SER-252, because any unexpected safety signal would be a major negative while lack of efficacy would still weaken confidence in the program.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.